Somaia Abd El-Karim

Dr. Somaia Abd El-Karim

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SESomaia Abd El-Karim
Somaia Abd El-Karim
HMHanaa S. Mohamed
Hanaa S. Mohamed
MAMohamed F. Abdelhameed
Mohamed F. Abdelhameed
AAAbd El-Galil E. Amr
Abd El-Galil E. Amr
AAAbdulrahman A. Almehizia
Abdulrahman A. Almehizia
ENEman S. Nossier
Eman S. Nossier

1 May 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SESomaia Abd El-Karim
Somaia Abd El-Karim
YSYasmin M. Syam
Yasmin M. Syam
AKAhmed M. El Kerdawy
Ahmed M. El Kerdawy
TATamer M. Abdelghany
Tamer M. Abdelghany

1 December 2015 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SESomaia Abd El-Karim
Somaia Abd El-Karim
MAManal Anwar
Manal Anwar
NMNeama A. Mohamed
Neama A. Mohamed
TNTamer Nasr
Tamer Nasr
SESamia Elseginy
Samia Elseginy

20 December 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
IOIsmail M. M. Othman
Ismail M. M. Othman
ZAZahra M. Alamshany
Zahra M. Alamshany
NTNada Y. Tashkandi
Nada Y. Tashkandi
MGMohamed A. M. Gad-Elkareem
Mohamed A. M. Gad-Elkareem
SESomaia Abd El-Karim
Somaia Abd El-Karim
ENEman Nossier
Eman Nossier
Deregulation of various protein kinases is considered as one of the important factors resulting in cancer development and metastasis, thus multi-targeting the kinase family is one of the most important strategies in current cancer therapy. This context represents the design and synthesis of two sets of derivatives bearing a pyrazoline-3-one ring conjugated either with a thieno[3,2-d]thiazole or with a dihydrothiazolo[4,5-d]thiazole scaffold via an NH linker, 3a–d and 5a–d respectively, using the pyrazolinone–thiazolinone derivative 1 as a key precursor. All the newly synthesized compounds were assessed in vitro for their anticancer activity against two cancer cell lines (MCF-7 and HepG-2). The safety profile of the most active cytotoxic candidates 1 and 3c was further examined against the normal cell line WI-38. The compounds 1 and 3c were further evaluated as multi-targeting kinase inhibitors against EGFR, VEGFR-2 and BRAFV600E, exhibiting promising suppression impact. Additionally, the latter compounds were investigated for their impact on cell cycle and apoptosis induction potential in the MCF-7 cell line. Moreover, the antimicrobial activity of all the new analogues was evaluated against a panel of Gram-positive and Gram-negative bacteria, yeast and fungi in comparison to streptomycin and amphotericin-B as reference drugs. Interestingly, both 1 and 3c showed the most promising microbial inhibitory effect. Molecular docking studies showed promising binding patterns of the compounds 1 and 3c with the prospective targets, EGFR, VEGFR-2 and BRAFV600E. Finally, additional toxicity studies were performed for the new derivatives which showed their good drug-like properties and low toxicity risks in humans.

1 September 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ASAladdin M. Srour
Aladdin M. Srour
NANesreen S. Ahmed
Nesreen S. Ahmed
SESomaia Abd El-Karim
Somaia Abd El-Karim
MAManal Anwar
Manal Anwar
SESalwa M. El-Hallouty
Salwa M. El-Hallouty